Safe and Adequate Blood Supply

Nearly 70 percent of primary immune deficient patients use intravenous immune globulin (IVIG) to maintain their health. IVIG is a pooled plasma derivative administered intravenously every three or four weeks that replaces antibodies in patients who are unable to adequately produce these protective proteins themselves. IDF works with the US FDA and the IVIG manufacturers to help to ensure a safe and adequate IVIG supply.